Is pathological aging a successful resistance against amyloid-beta or preclinical Alzheimer's disease?

Alzheimer's Research and Therapy

Volumn 6, Issue 3, 2014, Pages

  Murray, Melissa E ^a   Dickson, Dennis W ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; MEMBRANE METALLOENDOPEPTIDASE; SYNAPTOPHYSIN;

AGING; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; COHORT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOREACTIVITY; KINETICS; LONGITUDINAL STUDY; MICROVASCULATURE; NEUROPATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; R FACTOR; REVIEW; RISK FACTOR; SENILE PLAQUE; VASCULAR AMYLOIDOSIS; WHITE MATTER;

EID: 84899871185     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt254     Document Type: Review

References (21)

1. Neuropathological stageing of Alzheimer-related changes. H Braak, E Braak, Acta Neuropathol 1991 82 239 259 10.1007/BF00308809 1759558
2. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. DW Dickson, HA Crystal, LA Mattiace, DM Masur, AD Blau, P Davies, SH Yen, MK Aronson, Neurobiol Aging 1992 13 179 189 10.1016/0197-4580(92)90027-U 1311804
3. Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. CL Maarouf, ID Daugs, TA Kokjohn, DG Walker, JM Hunter, JC Kruchowsky, R Woltjer, J Kaye, EM Castano, MN Sabbagh, TG Beach, AE Roher, PLoS One 2011 6 27291 10.1371/journal.pone.0027291 22087282
4. Cerebral amyloid deposition and diffuse plaques in 'normal' aging: evidence for presymptomatic and very mild Alzheimer's disease. JC Morris, M Storandt, DW McKeel Jr, EH Rubin, JL Price, EA Grant, L Berg, Neurology 1996 46 707 719 10.1212/WNL.46.3.707 8618671
5. Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease. A Rijal Upadhaya, I Kosterin, S Kumar, CAF von Arnim, H Yamaguchi, M Fändrich, J Walter, DR Thal, Brain 2014 137 887 903 10.1093/brain/awt362 24519982
6. 'Preclinical' AD revisited: neuropathology of cognitively normal older adults. FA Schmitt, DG Davis, DR Wekstein, CD Smith, JW Ashford, WR Markesbery, Neurology 2000 55 370 376 10.1212/WNL.55.3.370 10932270 (Pubitemid 30654797)
7. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. GM Shankar, S Li, TH Mehta, A Garcia-Munoz, NE Shepardson, I Smith, FM Brett, MA Farrell, MJ Rowan, CA Lemere, CM Regan, DM Walsh, BL Sabatini, DJ Selkoe, Nat Med 2008 14 837 842 10.1038/nm1782 18568035
8. The pathogenesis of senile plaques. DW Dickson, J Neuropathol Exp Neurol 1997 56 321 339 10.1097/00005072-199704000-00001 9100663 (Pubitemid 27465015)
9. Diagnosis of Alzheimer's disease. ZS Khachaturian, Arch Neurol 1985 42 1097 1105 10.1001/archneur.1985.04060100083029 2864910 (Pubitemid 16236926)
10. Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. SE Monsell, C Mock, CM Roe, N Ghoshal, JC Morris, NJ Cairns, W Kukull, Neurology 2013 80 2121 2129 10.1212/WNL.0b013e318295d7a1 23645594
11. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. BG Perez-Nievas, TD Stein, HC Tai, O Dols-Icardo, TC Scotton, I Barroeta-Espar, L Fernandez-Carballo, EL de Munain, J Perez, M Marquie, A Serrano-Pozo, MP Frosch, V Lowe, JE Parisi, RC Petersen, MD Ikonomovic, OL Lopez, W Klunk, BT Hyman, T Gomez-Isla, Brain 2013 136 2510 2526 10.1093/brain/awt171 23824488
12. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). T Iwatsubo, A Odaka, N Suzuki, H Mizusawa, N Nukina, Y Ihara, Neuron 1994 13 45 53 10.1016/0896-6273(94)90458-8 8043280
13. Senile cerebral amyloidosis (pathological aging) and cognitive status predictions: a neuropathology perspective. DW Dickson, Neurobiol Aging 1996 17 936 937 discussion 945-947 10.1016/S0197-4580(96)00173-X 9363806 (Pubitemid 27022748)
14. Apolipoprotein E Immunoreactivity is Increased in Amyloid Deposits of Alzheimer's Disease, but not Pathological Aging or Diffuse Lewy Body Disease. DW Dickson, A Ivanushkin, J Heitner, S-H Yen, Research Advances in Alzheimer's Disease and Related Disorders Chichester: Wiley, Iqbal K, 1995 371 383 24718104
15. Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains. BD Moore, P Chakrabarty, Y Levites, TL Kukar, AM Baine, T Moroni, TB Ladd, P Das, DW Dickson, TE Golde, Alzheimers Res Ther 2012 4 18 10.1186/alzrt121 22621179
16. Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. RM Koffie, T Hashimoto, HC Tai, KR Kay, A Serrano-Pozo, D Joyner, S Hou, KJ Kopeikina, MP Frosch, VM Lee, DM Holtzman, BT Hyman, TL Spires-Jones, Brain 2012 135 2155 2168 10.1093/brain/aws127 22637583
17. Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. DS Wang, RB Lipton, MJ Katz, P Davies, H Buschke, G Kuslansky, J Verghese, SG Younkin, C Eckman, DW Dickson, J Neuropathol Exp Neurol 2005 64 378 385 15892294 (Pubitemid 40629127)
18. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. J Wang, DW Dickson, JQ Trojanowski, VM Lee, Exp Neurol 1999 158 328 337 10.1006/exnr.1999.7085 10415140 (Pubitemid 29382824)
19. Cortical thickness mediates the effect of beta-amyloid on episodic memory. S Villeneuve, BR Reed, M Wirth, CM Haase, CM Madison, N Ayakta, W Mack, D Mungas, HC Chui, C Decarli, MW Weiner, WJ Jagust, Neurology 2014 82 761 767 10.1212/WNL.0000000000000170 24489134
20. Neuritic plaque amyloid in Alzheimer's disease is highly racemized. R Shapira, GE Austin, SS Mirra, J Neurochem 1988 50 69 74 10.1111/j.1471-4159. 1988.tb13231.x 3121789 (Pubitemid 18023481)
21. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. AE Roher, JD Lowenson, S Clarke, C Wolkow, R Wang, RJ Cotter, IM Reardon, HA Zurcher-Neely, RL Heinrikson, MJ Ball, BD Greenberg, J Biol Chem 1993 268 3072 3083 8428986 (Pubitemid 23070928)